Cathepsin b-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy

HIGHLIGHTS

• who: Hanhee Cho and colleagues from the Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, KoreaDepartment of Materials Science and Engineering, Seoul National University, Seoul, Korea have published the paper: Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy, in the Journal: Pharmaceutics 2022, 14, 83. of /2022/
• what: The authors propose B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug Al-ProD that consists of a albumin-binding maleimide group B-cleavable peptide (FRRG) and doxorubicin. This study provides a promising approach for effective and safe . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.